Companion Diagnostics News on companion diagnostics and drug/test co-development. Jan 6, 2023 Agilent, Akoya to Commercialize Workflow Tools for Tissue Biomarker Analysis Jan 4, 2023 FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek Jan 4, 2023 Absent Resolution on FDA's LDT Oversight in 2022, Some Payors Began Advancing Their Own Requirements Premium Jan 4, 2023 Precision Oncology in 2022: New Drugs and Tests Amid Ongoing Access Barriers Premium Jan 4, 2023 Gene Expression Score IDs Breast Cancer Patients Responsive to Histone Deacetylase 6 Inhibitor Premium Dec 28, 2022 Mission Bio, Abiosciences to Develop Analytics For Studying Hematologic Cancers Dec 21, 2022 FDA Approves Foundation Medicine Assay as CDx for Certain NSCLC Therapies Dec 13, 2022 FDA Approves Mirati's Krazati for Advanced KRAS-Mutated Lung Cancer Dec 9, 2022 Guardant Health, AstraZeneca Partner on Liquid Biopsy CDx for Breast Cancer Drug Dec 9, 2022 Breast Cancer Patients Fare Better on Elacestrant With Longer CDK4/6 Inhibitor Treatment Dec 7, 2022 FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Nov 18, 2022 NeoGenomics, ImmunoGen Ink Testing Deal for Newly Approved Folate Receptor Drug Nov 15, 2022 FDA Approves ImmunoGen's Elahere for Folate Receptor Alpha-Positive Ovarian Cancer Oct 24, 2022 Molecular Tumor Board Therapy Matching Predicts Immunotherapy Best Responders Premium Oct 6, 2022 Tempus, Kartos Therapeutics to Develop CDx for Skin Cancer Therapy Oct 5, 2022 California Governor Vetoes Biomarker Test Coverage Bill Oct 4, 2022 FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients Sep 27, 2022 Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers Sep 21, 2022 Foundation Medicine, Day One Biopharmaceuticals to Develop CDx for Tovorafenib Sep 14, 2022 Biomarker Test Access for Precision Oncology Varies Widely in Europe, ESMO Survey Finds Premium Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer What's Popular? In Companion Diagnostics Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test Precision Oncology in 2022: New Drugs and Tests Amid Ongoing Access Barriers Premium Absent Resolution on FDA's LDT Oversight in 2022, Some Payors Began Advancing Their Own Requirements Premium Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug